UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $412,000 Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 15.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,995 shares of the company’s stock after buying an additional 5,746 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of Ginkgo Bioworks worth $412,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Shay Capital LLC acquired a new position in shares of Ginkgo Bioworks during the fourth quarter worth approximately $223,000. Point72 Asset Management L.P. acquired a new position in shares of Ginkgo Bioworks during the fourth quarter worth approximately $980,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Ginkgo Bioworks during the fourth quarter worth approximately $342,000. Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company’s stock worth $6,580,000 after buying an additional 523,571 shares during the last quarter. Finally, Coastal Bridge Advisors LLC lifted its holdings in shares of Ginkgo Bioworks by 1,609.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company’s stock worth $2,718,000 after buying an additional 260,627 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Stock Up 14.9%

Shares of DNA stock opened at $9.76 on Thursday. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $22.60. The firm has a market cap of $571.51 million, a PE ratio of -0.75 and a beta of 1.25. The stock has a 50 day moving average of $7.49 and a 200-day moving average of $9.06.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The business had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. As a group, equities analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.